当前位置:首页 > 报告详情

ATEA - JPM Healthcare Conference Slide Deck _2025_FINAL.pdf

上传人: c** 编号:603956 2025-02-03 22页 828.69KB

1、ATEA CorporatePresentationJanuary 2025DISCLAIMERSForward-Looking Statements This presentation contains“forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements are neither historical facts nor assurances of future performance.In

2、stead,they are based on our current beliefs,expectations and assumptions regarding the future of our business,future plans and strategies,our clinical results and other future conditions including without limitation the future of the HCV landscape and related commercial market opportunities.All stat

3、ements other than statements of historical facts contained in this presentation are forward-looking statements,including statements by Atea Pharmaceuticals,Inc.(the“Company”)regarding future results of operations and financial position,including our anticipated cash runway;business strategy;current

4、and prospective product candidates;anticipated milestone events;potential benefits of our product candidates and market opportunity;clinical trials,including,without limitation,anticipated initiation,enrollment,regulatory submission and data readout timelines;preclinical activities;product approvals

5、;manufacturing availability;degree of market acceptance of any products that may be approved;research and development costs;current and prospective collaborations;and prospects and opportunities for investors.In some cases,you can identify forward-looking statements by terms such as“may,”“will,”“sho

6、uld,”“expects,”“plans,”“anticipates,”“could,”“intends,”“targets,”“projects,”“contemplates,”“believes,”“estimates,”“predicts,”“potential”or“continue”or the negative of these terms or other similar expressions.The information in this presentation,including without limitation the forward-looking statem

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Atea Pharmaceuticals公司的产品Bemnifosbuvir (BEM) 和 Ruzasvir (RZR) 的治疗丙型肝炎(HCV)的固定剂量组合(FDC)药物。该药物在第二阶段临床试验中表现出了非常高的疗效,98%的患者在治疗12周后达到了病毒学缓解(SVR12),并且该药物的安全性良好,没有出现与药物相关的严重不良事件(SAEs)。此外,该药物的药物相互作用(DDI)风险较低,治疗持续时间短,且不受食物影响,这些特点使其成为潜在的“最佳治疗方案”。Atea计划于2025年1月与美国食品药品监督管理局(FDA)进行第三阶段临床试验的终期会议,以支持全球第三阶段临床试验。根据市场分析,BEM+RZR组合药物有望成为HCV治疗领域的主流药物,并可能成为市场上最受欢迎的直接作用抗病毒药物(DAA)。
什么是ATEC公司的主要产品? ATEC公司的HCV治疗药物BEM+RZR有哪些优势? ATEC公司的HCV治疗药物BEM+RZR预计何时上市?
客服
商务合作
小程序
服务号
折叠